Home › Linfoma di Burkitt › Maryland › Baltimore
Studi clinici su Linfoma di Burkitt a Baltimore, MD
8 studi su Linfoma di Burkitt cercano partecipanti presso sedi a Baltimore e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
In reclutamentoFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
In reclutamentoFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
In reclutamentoFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 1
- University of Maryland, Baltimore
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
In reclutamentoFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
In reclutamentoFase 1
- University of Maryland, Baltimore
Studi su Linfoma di Burkitt in altre città
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Boston, MA10 studi
- Durham, NC10 studi
- Aurora, CO10 studi
- Los Angeles, CA10 studi
Altri studi a Baltimore
- Cancro del polmone non a piccole cellule60 studi
- Cancro al seno47 studi
- Cancro alla prostata43 studi
- Cancro ai polmoni40 studi
- Cancro (tutti i tipi)37 studi
- Cancro colorettale31 studi
- Cancro pancreatico31 studi
- Cancro metastatico28 studi
- Obesità25 studi
- Insufficienza cardiaca24 studi
- Cancro della vescica24 studi
- Ictus22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.